A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 3, 2003, Pages 298-303

  Singh, Saranjit ^a   Mohan, B ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

FDC anti tuberculosis products; Instability; Packaging effects; Poor bioavailability

Indexed keywords

ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; ISONIAZID DERIVATIVE; PYRAZINAMIDE; RIFAMPICIN; RIFAMYCIN DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DECOMPOSITION; DRUG FORMULATION; DRUG MIXTURE; DRUG PACKAGING; DRUG STABILITY; HUMIDITY; PH; PILOT STUDY; PRIORITY JOURNAL; QUALITY CONTROL; SOLID STATE;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; DRUG COMBINATIONS; DRUG LABELING; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; ETHAMBUTOL; HUMANS; ISONIAZID; PILOT PROJECTS; PYRAZINAMIDE; RIFAMPIN; TABLETS; TIME FACTORS; TUBERCULOSIS;

EID: 0037344543     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Singh S, Mariappan T T, Sharda N, Kumar S, Chakraborti A K. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm Pharmacol Commun 2000; 6: 405-410.
2. Singh S, Mariappan T T, Sharda N, Singh B. Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions. Pharm Pharmacol Commun 2000; 6: 491-494.
3. Singh S, Mariappan T T, Shankar R, Sharda N, Singh B. A critical review of the probable reasons for the variable bioavailability of rifampicin from anti-tuberculosis fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm 2001; 228: 5-17.
4. Singh S. Efforts of the WHO/IUATLD to solve the problem of poor bioavailability of rifampicin from FDC anti-tuberculosis products: is a change required in the direction of the approach in the view of recent findings? Int J Tuberc Lung Dis 2001; 5: 880-882.
5. Acocella G. Human bioavailability studies. Bull Int Union Tuberc Lung Dis 1989; 64: 38-40.
6. Pillai G, Fourie P B, Padayatchi N, et al. Recent bioequivalence studies on fixed dose combination anti tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S309-S316.
7. Panchagnula R, Singh I, Kaur K J, Kaul C L. Bioequivalence study of rifampicin in fixed dose combination of rifampicin and isoniazid vs. separate formulations. Methods Find Exp Clin Pharmacol 1999; 21: 625-628.
8. Panchagnula R, Kaur K J, Singh I, Kaul C L. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S336-S342.
9. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Stability testing of new drug substances and products. Q1AR. Geneva: ICH, 2000.
10. Photostability testing of the new drug substances and products, Q1B. Geneva: ICH, 1996.
11. World Health Organization. Fixed-dose combination tablets for the treatment of tuberculosis, Report of an informal meeting held in Geneva, 27 April, 1999. Geneva: WHO.
12. Quality assurance of fixed-dose combinations of anti-tuberculosis medications. Proceedings of an IUATLD/WHO workshop. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S281-S387.
13. Taborsky C J, Foster M G, Lockhart H, Polgar B. Permeation of unit-dose blister market containers under USP and ICH conditions. Pharm Tech 2000; 24: 38-42.